Khilanani P, Chou T H, Kessel D
Cancer Res. 1978 Jan;38(1):181-4.
We have measured the plasma level of a fucosyltransferase in patients with acute myelogenous leukemia and non-Hodgkin's lymphoma at various stages of the disease and in normal controls. This enzyme transfers the sugar fucose from a guanosine diphosphate-L-fucose donor to high-molecular-weight acceptors with a terminal N-acetyl-glucosamine residue. The enzyme levels of fucosyltransferase in individuals free from disease and in patients with untreated leukemia or lymphoma were comparable. A substantial increase in plasma enzyme level was measured during drug-induced remissions, three weeks after drug therapy. The enzyme level fell to the normal range during unmaintained remissions inpatients with lymphomas; comparable information for the leukemia is not available since all remissions were drug maintained. These data, together with microscopic examination of marrow samples, indicate that the level of this fucosyltransferase is correlated with regeneration of a normal marrow population after chemotherapy. The enzyme assay may prove useful in defining normal bone marrow recovery and in timing cyclic combination chemotherapy in patients with neoplastic disease.
我们测定了急性髓性白血病和非霍奇金淋巴瘤患者在疾病不同阶段以及正常对照者血浆中岩藻糖基转移酶的水平。该酶将来自二磷酸鸟苷-L-岩藻糖供体的岩藻糖转移至具有末端N-乙酰葡糖胺残基的高分子量受体上。无疾病个体以及未经治疗的白血病或淋巴瘤患者的岩藻糖基转移酶水平相当。在药物诱导缓解期间,即药物治疗三周后,测得血浆酶水平大幅升高。淋巴瘤患者在未维持缓解期间,酶水平降至正常范围;由于白血病患者的所有缓解均通过药物维持,因此尚无关于白血病患者的类似信息。这些数据,连同骨髓样本的显微镜检查,表明该岩藻糖基转移酶的水平与化疗后正常骨髓细胞群的再生相关。该酶测定可能有助于确定正常骨髓恢复情况以及为肿瘤疾病患者安排周期性联合化疗的时间。